More transparent pricing would allow patients and families to make better decisions, but there are limitations to how reliably it promotes efficiency and market discipline.
AMA J Ethics. 2022;24(11):E1069-1074. doi:
10.1001/amajethics.2022.1069.
Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
AMA J Ethics. 2022;24(11):E1075-1082. doi:
10.1001/amajethics.2022.1075.
Sarosh Nagar, Leah Z. Rand, PhD, and Aaron S. Kesselheim, MD, JD, MPH
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.
AMA J Ethics. 2022;24(11):E1083-1090. doi:
10.1001/amajethics.2022.1083.
Amy D. Hendrix-Dicken joins Ethics Talk to discuss her article, coauthored with Drs Sarah J. Passmore, Michael A. Baxter, and Lauren K. Conway: “McGirt v Oklahoma and What Clinicians Should Know About Present-Day Child Abuse and Legacies of Forced Migration.”
Isabelle M. Mikell joins Ethics Talk to discuss her article, coauthored with Courtney L. Savage Hoggard and Dr Harald Schmidt: "What Should Be Roles of Federal Clinician Governors in Motivating Equity in Locally Coordinated Triage Protocols?"